Navigation Links
Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent
Date:9/2/2014

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the U.S. Patent and Trademark Office (PTO) has issued a patent related to NB32, the Company's investigational medication being evaluated for weight loss. NB32 is a fixed-dose combination of naltrexone sustained release (SR) and bupropion SR.

U.S. Patent No. 8,815,889 claims methods for treating insulin resistance using a composition including naltrexone and bupropion. The patent expires in 2024. If NB32 is approved for use in the United States, Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and Drug Administration. A counterpart application to this patent has issued in Europe and other international jurisdictions.

"As we ready NB32 for commercialization and plan for lifecycle development, the issuance of this patent adds to our growing intellectual property portfolio and, we believe, enhances the value of the asset," said Michael Narachi, CEO of Orexigen.

Intellectual Property Protecting NB32NB32 is currently protected by U.S. patent number 7,375,111 and U.S. patent number 7,462,626, which Orexigen refers to collectively as the Weber/Cowley patents and which are expected to expire in 2025/2024. The Weber/Cowley patents cover the current composition of NB32 and methods of administering it to treat obesity. Orexigen and/or licensors have filed a number of international counterparts to the Weber/Cowley patents in foreign countries. A European counterpart application to the Weber/Cowley patent has issued in the European Patent Office, or EPO, and provides protection for NB32 in the various EPO countries in which the patent has been registered. Orexigen has also filed patent applications, directed to various treatment and formulation aspects of NB32, in the United States and certain foreign countries under the Patent Cooperation Treaty, or PCT. Use of a proprietary tri-layer NB32 tablet for weight loss is protected in the United States by U.S. patent numbers 8,088,786 and 8,318,788, which are expected to expire in February 2029 and November 2027, respectively. In addition, the dose escalation schedule of Contrave is protected by U.S. patent 8,722,085, which is expected to expire in November 2027. Orexigen has filed other patent applications in the United States and other parts of the world with the potential, if the patents issue, to extend intellectual property protection as late as 2034.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB32. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize NB32 in the United States. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward‐Looking Statements 
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding: the potential for U.S. Patent No. 8,815,889 to be listed in the Orange Book; the potential for U.S. Patent No. 8,815,8891 to enhance the value of NB32; the expected expiration dates of the intellectual property covering NB32; and the potential for the FDA or CHMP to approve NB32 in 2014.  Inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the potential for a generic competitor to successfully argue that U.S. Patent No. 8,815,889 should not be listed in the Orange Book or invalidate one or more of the patents covering NB32; the potential for the FDA and/or the CHMP to not approve NB32 in 2014; the worldwide therapeutic and commercial value of NB32; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission August 8, 2014 and its other reports, which are available from the SEC's website (www.sec.gov) and on Orexigen's website (www.orexigen.com) under the heading "Investor Relations." All forward‐looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.Orexigen Contact:

Media Contact: McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
8. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
9. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
10. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
11. Orexigen Receives CHMP Day 180 List of Outstanding Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... R&D program for the development of future natural products for ... research and development center in Israel ... Stockton has a variety of products adapted ... active in more than 35 counties worldwide. ... flagship product Timorex Gold ® is used to control ...
(Date:2/5/2016)... 2016 ATCC, the premier global biological materials ... medical and life science researchers that are working to ... CDC website . --> ... is a single-stranded RNA virus of the Flaviviridae family, ... and Chikungunya Viruses. Zika virus is transmitted to humans ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ., ... interactive FDA compliance training course, Writing Effective SOPs (Standard ... interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step by ...
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
Breaking Biology Technology:
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ) ... "Global Facial Recognition Market 2016-2020" report ... ) has announced the addition of the ... report to their offering. --> ... announced the addition of the "Global ...
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
Breaking Biology News(10 mins):